North West Cancer Research is committed to understanding cancer. To build on previous success in the area, our research portfolio must be sufficiently flexible to incorporate new technologies and advances in treatment.
Our research will help cancer patients in our region, investing in the understanding of the biology of cancer, research into potential treatments and develop our work on prevention and early diagnosis. This must be undertaken in addition to systematically linking the research activities of the charity with appropriate public engagement activities.
Thus our research will improve cancer outcomes, engage the broader public and increase the knowledge flow from laboratories and clinical settings to patients and vice versa.
We will continue our focus of investing in research which will further develop our understanding of the biology of cancer whilst continuing to invest in research into potential approaches to improve the treatment of cancer and patient care. This should build upon our existing major research project funding and particularly the continuously emerging benefits from the discoveries of the molecular mechanisms underlying pathogenesis in various cancers.
2.1 To promote and carry out research into cancer, its diagnosis and its treatment and to disseminate the results of such research to the public. To achieve this we will:
The range of research we will cover will include basic, translational and preventative studies.
2.2 The research that we fund should also support our longer term strategic aims, namely that:
2.3 Our strategic intentions are grounded on three key principles:
2.4 To achieve this we aim to work with a range of partners to allow us to fund a broad portfolio of research that is in parts:
3.1 We do not prioritise specific types of cancer research and we will avoid costly infrastructure investment, direct clinical care or high overheads. Our primary aim is to invest in people and high quality projects and to continue to expand our research capacity.
3.2 Potential investment areas will generally cover:
3.3 We remain committed to putting some funds into small and innovative research grants that may potentially lead to breakthrough/pathfinders, that could in themselves create bigger schemes this can include basic science (including cell division and replication and cell signalling), cancer pharmacology (including early drug development) and early clinical trials. These initiatives can also build upon existing academic and treatment expertise across our regional footprint.
We have a robust application process with supporting information to guide applicants as to what is acceptable which then leads onto a review process including external assessors and final recommendations being made by our Scientific Committee.
This Research Strategy will be reviewed annually.